{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-281657","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.876580+00:00","generated_at":"2026-05-16T19:55:48.421207+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"confidence":"high","headline":"IO Biotech Q3: Phase 3 melanoma trial narrowly misses PFS endpoint; cash $30.7M, runway to Q1 2026","bullets":["Phase 3 IOB-013 trial in advanced melanoma showed PFS improvement but narrowly missed statistical significance; FDA meeting in December for new registrational trial design.","Q3 total operating expenses $19.4M, down from $26.5M YoY; R&D expenses $13.7M vs $20.2M prior year.","Cash and equivalents $30.7M as of Sep 30, 2025, down from $60.0M at Dec 31, 2024; expects to fund operations through Q1 2026.","Cash increased $2.5M in Q3 from €12.5M EIB loan drawdown and $6.6M net ATM proceeds.","Pre-clinical data for pipeline candidates IO112 (arginase 1) and IO170 (TGF-β) presented at SITC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-281657","json":"https://secwatch.observer/filing/0001193125-25-281657.json","markdown":"https://secwatch.observer/filing/0001193125-25-281657.md","text":"https://secwatch.observer/filing/0001193125-25-281657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312525281657/0001193125-25-281657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312525281657/d36523d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:55:48.421207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}